On the stock market since 2023, it operates in the world of health and science. It has 88 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $296.2M in the vault; even if every debt were paid off, $285.7M would remain.
A loss of $68.6M against $0 in annual sales.
This stock swings about 3.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, RYZB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RYZB is a high-risk stock — not yet profitable, and its future rides on its product catching on.